A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...

Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer ...

A recent study by Emory University researchers provides new insights into why the mRNA vaccines developed to fight COVID-19 ...

Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...

The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.